Adverum Biotechnologies, Inc. — Investor Relations & Filings

Adverum Biotechnologies, Inc. is a clinical-stage company developing gene therapies for highly prevalent ocular diseases. The company's primary goal is to establish single-administration intravitreal (IVT) gene therapy as a new standard of care, aspiring to develop functional cures that restore vision and prevent blindness. Its lead product candidate, Ixo-vec (ixoberogene soroparvovec), targets wet age-related macular degeneration (wet AMD). Adverum utilizes a proprietary adeno-associated virus (AAV) vector platform designed to transform retinal cells into biofactories for the long-term production of therapeutic proteins. This approach aims to replace the need for frequent eye injections with a durable, in-office treatment.